Premium
Nanovector‐mediated drug delivery for spinal cord injury treatment
Author(s) -
Caron Ilaria,
Papa Simonetta,
Rossi Filippo,
Forloni Gianluigi,
Veglianese Pietro
Publication year - 2014
Publication title -
wiley interdisciplinary reviews: nanomedicine and nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 72
eISSN - 1939-0041
pISSN - 1939-5116
DOI - 10.1002/wnan.1276
Subject(s) - medicine , spinal cord injury , nanomedicine , spinal cord , drug delivery , drug , disease , bioinformatics , intensive care medicine , pharmacology , pathology , biology , chemistry , materials science , organic chemistry , psychiatry , nanoparticle , nanotechnology
Spinal cord injury (SCI) is the result of a traumatic primary event followed by a so‐called secondary injury, which is characterized by a large spectrum of biochemical cellular pathways able to spread the lesion, worsening neurologic recovery. A growing number of potential therapeutic interventions to counteract different neurodegenerative mechanisms of SCI have been proposed, but they did not show relevant efficacy when translated as clinical treatments. Different reasons could explain these disappointing results: on one side the multifactorial evolution of SCI after the primary injury that limits the beneficial effect of just one targeted treatment and, on the other, the restricted access of pharmacological therapies to the spinal cord. For these reasons, recently, a growing interest has been shown in the development of alternative delivery strategies to administer drugs and/or biological/cellular therapies into the spine (hydrogel and nanoparticles). This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease Implantable Materials and Surgical Technologies > Nanotechnology in Tissue Repair and Replacement